Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene.
Rath MG, Fathali-Zadeh F, Langheinz A, Tchatchou S, Voigtländer T, Heil J, Golatta M, Schott S, Drasseck T, Behnecke A, Burgemeister AL, Evers C, Bugert P, Junkermann H, Schneeweiss A, Bartram CR, Sohn C, Sutter C, Burwinkel B. Rath MG, et al. Among authors: sohn c. Breast Cancer Res Treat. 2012 Jun;133(2):725-34. doi: 10.1007/s10549-011-1917-0. Epub 2012 Jan 8. Breast Cancer Res Treat. 2012. PMID: 22228431
Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk.
Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Müller H, Arndt V, Brenner H, Sohn C, Burwinkel B. Yang R, et al. Among authors: sohn c. Breast Cancer Res Treat. 2011 Jun;127(2):549-54. doi: 10.1007/s10549-010-1244-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21046227
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM, Sutter C, Mittnacht M, Klaes R, Schaefer D, Evers C, Burgemeister AL, Goehringer C, Dikow N, Heil J, Golatta M, Schott S, Schneeweiss A, Bugert P, Sohn C, Bartram CR, Burwinkel B. Surowy HM, et al. Among authors: sohn c. Breast Cancer Res Treat. 2014 Jun;145(2):451-60. doi: 10.1007/s10549-014-2943-5. Epub 2014 Apr 12. Breast Cancer Res Treat. 2014. PMID: 24728577
DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
Yang R, Pfütze K, Zucknick M, Sutter C, Wappenschmidt B, Marme F, Qu B, Cuk K, Engel C, Schott S, Schneeweiss A, Brenner H, Claus R, Plass C, Bugert P, Hoth M, Sohn C, Schmutzler R, Bartram CR, Burwinkel B. Yang R, et al. Among authors: sohn c. Int J Cancer. 2015 Apr 15;136(8):1845-55. doi: 10.1002/ijc.29205. Epub 2014 Sep 24. Int J Cancer. 2015. PMID: 25213452 Free article.
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Among authors: sohn c. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Circulating microRNAs in plasma as early detection markers for breast cancer.
Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Cuk K, et al. Among authors: sohn c. Int J Cancer. 2013 Apr 1;132(7):1602-12. doi: 10.1002/ijc.27799. Epub 2012 Sep 14. Int J Cancer. 2013. PMID: 22927033 Free article.
1,180 results